Retinal Stem Cell Consortium

NSCI created the Retinal Stem Cell Consortium (RSSC) to generate stem cell-based therapies to treat dry Age-related Macular Degeneration (AMD). The RSSC consists of leading stem cell scientists, retinal researchers, ophthalmologists, and representatives of biotechnology companies from around the world working to create a seamless pathway from the laboratory to the clinic.

The RSSC research efforts targets diseases with great impact on patients, families, and our economy. One in five people over age 75 suffers from dry AMD, which is the leading cause of blindness in the US. Our research harnesses stem cells to generate therapies for Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, retinoblastoma, and choroidal melanoma. Our approaches include the activation of resident retinal stem cells to stimulate repair, generating stem cells for replacement of damaged retina, and the use of stem cells to model retinal disease for drug discovery. The RSSC brings scientists together to solve the complex and multi-faceted application of stem cell research to blinding retinal disease.